PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Compugen Ltd. (CGEN)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

IL0010852080

CUSIP

M25722105

Sector

Healthcare

IPO Date

Aug 11, 2000

Highlights

Market Cap

$142.36M

EPS (TTM)

$0.03

PE Ratio

53.00

Total Revenue (TTM)

$59.85M

Gross Profit (TTM)

$50.59M

EBITDA (TTM)

$10.58M

Year Range

$1.35 - $3.03

Target Price

$4.00

Short %

1.47%

Short Ratio

6.42

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
CGEN vs. VOO CGEN vs. SGMO
Popular comparisons:
CGEN vs. VOO CGEN vs. SGMO

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Compugen Ltd., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-20.00%-10.00%0.00%10.00%JulyAugustSeptemberOctoberNovemberDecember
-18.30%
7.20%
CGEN (Compugen Ltd.)
Benchmark (^GSPC)

Returns By Period

Compugen Ltd. had a return of -23.23% year-to-date (YTD) and -17.84% in the last 12 months. Over the past 10 years, Compugen Ltd. had an annualized return of -16.27%, while the S&P 500 had an annualized return of 10.96%, indicating that Compugen Ltd. did not perform as well as the benchmark.


CGEN

YTD

-23.23%

1M

5.56%

6M

-18.28%

1Y

-17.84%

5Y*

-23.06%

10Y*

-16.27%

^GSPC (Benchmark)

YTD

23.00%

1M

-0.84%

6M

7.20%

1Y

24.88%

5Y*

12.77%

10Y*

10.96%

Monthly Returns

The table below presents the monthly returns of CGEN, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202421.72%7.05%-0.00%-25.19%12.44%-22.58%5.36%18.64%-13.81%-11.60%-0.62%-23.23%
202321.39%-9.05%-11.16%-15.95%72.88%11.76%1.75%-1.72%-18.42%-18.28%-12.80%198.78%176.65%
2022-17.44%-12.96%4.21%-26.09%-22.27%0.00%-12.97%-27.33%-43.85%44.87%26.08%-40.36%-83.36%
20210.41%-23.27%-7.93%0.47%-11.01%7.81%-18.00%3.39%-14.96%8.71%-31.90%-2.71%-64.49%
202020.81%25.97%-19.96%99.59%6.21%-2.40%-4.06%19.99%-6.02%-20.68%-0.39%-5.69%103.19%
201958.99%-0.29%20.35%-15.46%-20.00%37.14%-15.62%18.83%9.87%21.28%18.71%-2.13%174.65%
201820.00%33.33%11.25%-21.35%7.14%-12.00%-4.55%23.81%-1.28%-20.00%12.34%-37.28%-13.20%
2017-6.86%-10.53%1.18%-5.81%18.52%-20.83%6.58%-24.69%24.59%-21.05%-18.33%2.04%-50.98%
2016-26.29%0.85%17.47%21.51%2.65%-6.90%2.62%5.71%-10.38%-8.73%5.22%-15.70%-20.19%
2015-6.84%7.73%-15.67%-9.08%10.45%-1.98%-11.53%-19.87%5.08%19.73%22.78%-15.92%-23.29%
201420.89%4.81%-7.32%-10.85%-13.55%10.99%-5.23%4.46%-3.71%-16.69%-2.38%19.51%-6.93%
201310.16%-0.55%-5.94%18.15%-2.50%-7.02%-2.58%83.55%5.66%-2.53%3.90%-13.86%81.91%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of CGEN is 33, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of CGEN is 3333
Overall Rank
The Sharpe Ratio Rank of CGEN is 3131
Sharpe Ratio Rank
The Sortino Ratio Rank of CGEN is 3434
Sortino Ratio Rank
The Omega Ratio Rank of CGEN is 3434
Omega Ratio Rank
The Calmar Ratio Rank of CGEN is 3333
Calmar Ratio Rank
The Martin Ratio Rank of CGEN is 3333
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Compugen Ltd. (CGEN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for CGEN, currently valued at -0.33, compared to the broader market-4.00-2.000.002.00-0.331.83
The chart of Sortino ratio for CGEN, currently valued at -0.03, compared to the broader market-4.00-2.000.002.004.00-0.032.46
The chart of Omega ratio for CGEN, currently valued at 1.00, compared to the broader market0.501.001.502.001.001.34
The chart of Calmar ratio for CGEN, currently valued at -0.26, compared to the broader market0.002.004.006.00-0.262.72
The chart of Martin ratio for CGEN, currently valued at -0.73, compared to the broader market0.0010.0020.00-0.7311.89
CGEN
^GSPC

The current Compugen Ltd. Sharpe ratio is -0.33. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Compugen Ltd. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.00JulyAugustSeptemberOctoberNovemberDecember
-0.33
1.83
CGEN (Compugen Ltd.)
Benchmark (^GSPC)

Dividends

Dividend History


Compugen Ltd. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-92.19%
-3.66%
CGEN (Compugen Ltd.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Compugen Ltd.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Compugen Ltd. was 97.90%, occurring on Nov 24, 2008. Recovery took 2953 trading sessions.

The current Compugen Ltd. drawdown is 92.19%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-97.9%Sep 6, 20002066Nov 24, 20082953Aug 19, 20205019
-97.28%Aug 26, 2020810Nov 13, 2023
-15.03%Aug 15, 20004Aug 18, 20002Aug 22, 20006
-2.06%Aug 20, 20201Aug 20, 20203Aug 25, 20204
-1%Aug 24, 20001Aug 24, 20001Aug 25, 20002

Volatility

Volatility Chart

The current Compugen Ltd. volatility is 14.64%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%JulyAugustSeptemberOctoberNovemberDecember
14.64%
3.62%
CGEN (Compugen Ltd.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Compugen Ltd. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an assessment of the market value of Compugen Ltd. compared to its peers in the Biotechnology industry.


PE Ratio
200.0400.0600.053.0
The chart displays the price to earnings (P/E) ratio for CGEN in comparison to other companies of the Biotechnology industry. Currently, CGEN has a PE value of 53.0. This PE ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.
PEG Ratio
-1,000.0-800.0-600.0-400.0-200.00.00.0
The chart displays the price to earnings to growth (PEG) ratio for CGEN in comparison to other companies of the Biotechnology industry. Currently, CGEN has a PEG value of 0.0. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Compugen Ltd..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab